GlassScriptPhysician profile
Divya Angra
NPI 1053844530
$5,856.93
in general payments reported to CMS, 2019-2025
24 companies · $349 in 2025
The $349 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2021: $708 · 2022: $2,380 · 2023: $1,379 · 2024: $826 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,122 · Education: $432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.27 |
| Education | $431.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,036.22 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $912.65 | 2021-2025 | Tremfya |
| Incyte Corporation | $508.19 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $459.67 | 2021-2025 | Dupixent |
| Genzyme Corporation | $414.19 | 2021-2024 | |
| Galderma Laboratories, L.P. | $370.16 | 2022-2023 | Aklief, Oracea, Twyneo |
| Lilly USA, LLC | $332.62 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Scientific Affairs, LLC | $212.69 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $194.38 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $181.10 | 2021-2024 | Absorica Ld, Winlevi |
| Dermavant Sciences, INC. | $179.53 | 2023-2024 | Vtama |
| Pfizer INC. | $165.68 | 2022-2023 | |
| Amgen INC. | $153.57 | 2022-2024 | Otezla, Enbrel |
| E.R. Squibb & Sons, L.L.C. | $152.08 | 2021-2024 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $117.24 | 2021-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $96.22 | 2022-2023 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.47 | 2022-2024 | Spevigo |
| Arcutis Biotherapeutics, INC. | $71.07 | 2023-2025 | Zoryve |
| Ucb, INC. | $63.00 | 2022-2025 | Bimzelx |
| Helsinn Therapeutics (U.S.), INC. | $60.69 | 2022-2023 | Valchlor |
| Mayne Pharma Commercial LLC | $32.73 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.03 | 2023 | Arazlo, Duobrii, Jublia |
| Epi Health, LLC | $12.67 | 2022 | |
| Biofrontera INC. | $12.08 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divya Angra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.